At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 12 Oct 1998 New profile
- 06 Oct 1998 Preclinical development for Hyperlipidaemia in USA (Unknown route)